APHA:TSX-Aphria Inc (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | TSX

Last Closing Price

CAD 16.55

Change

0.00 (0.00)%

Market Cap

CAD 4.44B

Volume

9.61M

Avg Analyst Target

N/A

Avg User Target

CAD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


APHA Stock Forecast & Price:
Based on the Aphria Inc stock forecasts from 0 analysts, the average analyst target price for Aphria Inc is not available over the next 12 months. Aphria Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aphria Inc is Neutral, which is based on 1 positive signals and 1 negative signals. At the last closing, Aphria Inc’s stock price was CAD 16.55. Aphria Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

About Aphria Inc (APHA:CA:TSX)

Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Sole ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-30 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BHC:CA Bausch Health Companies Inc

+0.03 (+0.32%)

CAD3.44B 50.05 11.57
TLRY:CA Tilray Inc

-0.10 (-2.56%)

CAD2.16B 6.96 -9.92
WEED:CA Canopy Growth Corp

-0.07 (-1.83%)

CAD1.84B N/A -0.86
CRON:CA Cronos Group Inc

-0.15 (-3.73%)

CAD1.52B 46.76 -0.62
GUD:CA Knight Therapeutics Inc

-0.02 (-0.38%)

CAD0.61B 41.51 28.03
ACB:CA Aurora Cannabis Inc

-0.02 (-1.18%)

CAD0.51B 1,171.00 -0.23
OGI:CA OrganiGram Holdings Inc

-0.01 (-0.81%)

CAD0.40B -99,999.99 -768.87
DHT-UN:CA DRI Healthcare Trust

-0.13 (-1.68%)

CAD0.30B 11.71 N/A
TH:CA Theratechnologies Inc.

+0.13 (+4.13%)

CAD0.30B 954.70 -10.18
HLS:CA HLS Therapeutics Inc

-0.01 (-0.11%)

CAD0.29B N/A 17.77

ETFs Containing APHA:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 44.75% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.75% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 118.13% N/A N/A N/A N/A
Risk Adjusted Return 37.88% N/A N/A N/A N/A
Market Capitalization 4.44B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 57.08 N/A N/A N/A N/A
Price/Book Ratio 5.59 N/A N/A N/A N/A
Price / Cash Flow Ratio -33.19 N/A N/A N/A N/A
EV/EBITDA 598.01 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -34.14% N/A N/A N/A N/A
Return on Invested Capital -0.06% N/A N/A N/A N/A
Return on Assets -1.31% N/A N/A N/A N/A
Debt to Equity Ratio 22.09% N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.52 N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 2.62 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.